Decades of our own scientific investigation augmented by the work of others have elucidated that antibody therapeutics can result in meaningful clinical benefit for patients with the right combination of targeting the appropriate epitope, optimal binding strength, and the right clinical trial design with the appropriate endpoints in the right patient population.
Increasingly, these elements are aligning, and because of advances in our knowledge that informs the basic, clinical and regulatory sciences, we find ourselves with an expanding pipeline of investigational therapies.
While we are modality agnostic, we have deep expertise in antibody targeting and leverage insights and understanding around neurological dysfunction and the biology of misfolded proteins to develop a diverse pipeline that also includes small molecule and vaccine approaches. Advances in clinical trial design have revealed a path forward that makes developing new therapies possible, targeting the pathogenic proteins that underlie progressive and fatal neurodegenerative and peripheral amyloid diseases to address areas of high unmet need for patients.
Learn more about Prothena’s pipeline